What can Merck afford to buy now? ‘ANYTHING’ it wants
With Keytruda bulling its way past the $5 billion mark for Q2 sales, you could say that the top execs at Merck can be believed when they say how keenly interested they are in using its cash reserves for new M&A and licensing deals. Just don’t ask what they’re negotiating to buy right now.
The analysts largely tiptoed around the biggest buzz about Merck today: that it’s engaged in discussions to buy Seagen for $40 billion-plus. They’re a polite bunch that needs to be on a first-name basis with CEO Rob Davis. But Davis was willing to emphasize that the pharma giant has the means and the intent to do more deals.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.
